Merrimack Pharma (MACK) Reports Q4 Loss of $0.89
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Merrimack Pharmaceuticals (MACK) PT Lowered to $12 at Baird
March 12, 2018 11:10 AM EDTBaird lowered its price target on Merrimack Pharmaceuticals (NASDAQ: MACK) to $12.00 (from $15.00) while maintaining a Neutral rating.
Analsyt Michael Ulz said while multiple readouts are expected later this year, they are incrementally cautious and reiterate our Neutral rating.
... More